To arrange an interview, please contact the NHLBI Communications Office at 301-496-4236 or email@example.com.
W. Keith Hoots, M.D., is the director of the Division of Blood Diseases and Resources at the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH). In this role, Dr. Hoots plans and directs research and research training on the causes and prevention of blood diseases and disorders. He also oversees research to assure the adequacy and safety of the Nation's blood supply.
Dr. Hoots’ major interests involve the management and diagnosis of congenital and acquired bleeding disorders and clotting disorders. His work includes the creation of longitudinal follow-up of hemophilia cohorts with HIV and hepatitis, gene therapy trials for Hemophilia A and B, clinical trials of new clotting concentrates for Hemophilia A and B, and the impact of care and clotting factor product on Hemophilia patient outcomes. He also has a 20-year interest in the diagnosis and treatment of diffuse intravascular coagulation (DIC), in particular DIC in head trauma.
Having completed his training as the HIV epidemic was evolving in hemophilia patients, Dr. Hoots has been intimately involved in the development of safe coagulation factor products. By the late 1980s, he returned to the hemostasis focus which initially attracted him to the field, and he has continued to be a productive investigator and collaborator. He has a strong interest in global collaborations and in developing public-private partnerships and completed his sabbatical in Belgium.
Prior to joining the NHLBI in 2009, Dr. Hoots worked at the University of Texas (UT) Medical School at Houston where he was professor of pediatrics and the division head of pediatric hematology; section head of pediatric hematology, UT M.D. Anderson Cancer Center; and medical director, Gulf States Hemophilia and Thrombophilia Treatment Center. Dr. Hoots also directed the fellowship program at M.D. Anderson.
Dr. Hoots received his Bachelor of Arts in English and chemistry and his Doctor of Medicine from the University of North Carolina (UNC) in Chapel Hill, N.C. While a senior at UNC, he worked in the hemostasis laboratory of Dr. Kenneth Brinkhous. He then completed his pediatric internship and residency at Children's Medical Center, Parkland Memorial Hospital in Dallas, Texas. He returned to UNC for his fellowship in pediatric hematology oncology and worked in the laboratory of Dr. Harold Roberts. Dr. Hoots then joined the faculty at M.D. Anderson.
Dr. Hoots is a past member of the U.S. Department of Health and Human Services Blood Safety and Availability Advisory Committee to the Secretary of Health, past chair of the Medical and Scientific Advisory Committee for the National Hemophilia Foundation, and subcommittee co-chair of the DIC Subcommittee of International Society of Thrombosis and Hemostasis. He was also an associate editor for Seminars in Thrombosis and Hemostasis and served on the editorial boards of Haemophilia, Haemophilia Forum, and the International Monitor on Hemophilia. He is a former president of the Hemophilia Research Society of North America.
Areas of expertise: congenital and acquired bleeding disorders, clotting disorders, hemophilia, HIV and hepatitis, and pediatric non-malignant hematology.
September 9, 2014
NIH-convened panel recommends expanded adoption of drug and transfusion treatments for individuals with sickle cell disease
An expert panel has recommended expanded adoption of the drug hydroxyurea for the care of people with sickle cell disease, according to a report issued today. The report also suggests that clinicians give periodic blood transfusions to children with the disease to reduce stroke risk. According to the panel, both treatments are underutilized.
September 14, 2012
: Circulation Research
On the value of portfolio diversity in heart, lung, and blood research
Zorina S. Galis, Ph.D., W. Keith Hoots, M.D., James P. Kiley, Ph.D., and Michael S. Lauer, M.D., NHLBI
Just as in other fields, scientific diversity has been and continues to be critical for the success of HLB research.